#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Internal Medicine / 2019 - 2

IL-1 family cytokines in chronic inflammatory disorders

Czech version

Authors: Ilja Stříž
Authors‘ workplace: Pracoviště klinické a transplantační imunologie IKEM, Praha
Published in: Vnitř Lék 2019; 65(2): 81-85
Category:

Overview

IL-1 family represent a group of structurally related cytokines with prevailing pro-inflammatory (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β a IL-37γ) or anti-inflammatory (IL-1Ra, IL-36Ra, IL-38, IL-37) effects. They are involved not only in defense mechanisms and physiological modulation of homeostatic processes, but also in the imunopathogenesis of many diseases including rheumatoid arthritis, inflammatory bowel disease, autoimmune and auto-inflammatory diseases. Recently, advances in biologic therapy enabled blocking of IL-1α, IL-1β, IL-18, and IL-33 with new monoclonal antibodies, soluble receptors, or recombinant binding proteins.

Keywords:

Cytokines – inflammation – interleukin 1

Sources

  1. Striz I, Brabcova E, Kolesar L et al. Cytokine networking of innate immunity cells: a potential target of therapy. Clin Sci (Lond) 2014; 126(9): 593–612. Dostupné z DOI: <http://dx.doi.org/10.1042/CS20130497>.

  2. van de Veerdonk FL, Netea MG. New Insights in the Immunobiology of IL-1 Family Members. Frontiers in immunology 2013; 4: 167. Dostupné z DOI: <http://dx.doi.org/10.3389/fimmu.2013.00167>.

  3. Thomas C, Bazan JF, Garcia KC. Structure of the activating IL-1 receptor signaling complex. Nat Struct Mol Biol 2012; 19(4): 455–457. Dostupné z DOI: <http://dx.doi.org/10.1038/nsmb.2260>.

  4. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev 2018; 281(1): 8–27.Dostupné z DOI: <http://dx.doi.org/10.1111/imr.12621>.

  5. Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23(5): 479–490. Dostupné z DOI: <http://dx.doi.org/10.1016/j.immuni.2005.09.015>.

  6. Brabcova E, Kolesar L, Thorburn E et al. Chemokines induced in human respiratory epithelial cells by IL-1 family of cytokines. Folia Biol (Praha) 2014; 60(4): 180–186.

  7. Hoshino T, Wiltrout RH, Young HA. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol 1999; 162(9): 5070–5077.

  8. Fujita K, Ewing CM, Isaacs WB et al. Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int J Cancer 2011; 129(2): 424–432. Dostupné z DOI: <http://dx.doi.org/10.1002/ijc.25705>.

  9. Xie Y, Li Y, Cai X et al. Interleukin-37 suppresses ICAM-1 expression in parallel with NF-kappaB down-regulation following TLR2 activation of human coronary artery endothelial cells. Int Immunopharmacol 2016; 38: 26–30. Dostupné z DOI: <http://dx.doi.org/10.1016/j.intimp.2016.05.003>.

  10. Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol 2015; 97(4): 645–652. Dostupné z DOI: <http://dx.doi.org/10.1189/jlb.3RI1014–495R>.

  11. Gunther S, Sundberg EJ. Molecular determinants of agonist and antagonist signaling through the IL-36 receptor. J Immunol 2014; 193(2): 921–930. Dostupné z DOI: <http://dx.doi.org/10.4049/jimmunol.1400538>.

  12. Mora J, Schlemmer A, Wittig I et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J Mol Cell Biol 2016. pii: mjw006. Dostupné z DOI: <http://dx.doi.org/10.1093/jmcb/mjw006>.

  13. Danis VA, March LM, Nelson DS et al. Interleukin-1 secretion by peripheral blood monocytes and synovial macrophages from patients with rheumatoid arthritis. Journal Rheumatol1987; 14(1): 33–39.

  14. Firestein GS, Boyle DL, Yu C et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994; 37(5): 644–652.

  15. Joosten LA, Radstake TR, Lubberts E et al. Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 2003; 48(2): 339–347. Dostupné z DOI: <http://dx.doi.org/10.1002/art.10814>.

  16. Matsuyama Y, Okazaki H, Hoshino M et al. Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1beta signaling and a poor clinical response. Rheumatol Int 2012; 32(5): 1397–1401. Dostupné z DOI: <http://dx.doi.org/10.1007/s00296–011–1854–6>.

  17. Boutet MA, Bart G, Penhoat M et al. Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn‘s disease. Clin Exp Immunol 2016; 184(2): 159–173. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12761>.

  18. Xia L, Shen H, Lu J. Elevated serum and synovial fluid levels of interleukin-37 in patients with rheumatoid arthritis: Attenuated the production of inflammatory cytokines. Cytokine 2015; 76(2): 553–557. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cyto.2015.06.005>.

  19. Italiani P, Manca ML, Angelotti F et al. IL-1 family cytokines and soluble receptors in systemic lupus erythematosus. Arthritis Res Ther 2018; 20(1): 27. Dostupné z DOI: <http://dx.doi.org/10.1186/s13075–018–1525-z>.

  20. Wu GC, Li HM, Wang JB et al. Elevated plasma interleukin-37 levels in systemic lupus erythematosus patients. Lupus 2016; 25(12): 1377–1380. Dostupné z DOI: <http://dx.doi.org/10.1177/0961203316646462>.

  21. Liuqing W, Liping X, Hui S et al. Elevated IL-37, IL-18 and IL-18BP serum concentrations in patients with primary Sjogren‘s syndrome. J Investig Med 2017; 65(3): 717–721. Dostupné z DOI: <http://dx.doi.org/10.1136/jim-2016–000301>.

  22. Ciccia F, Accardo-Palumbo A, Alessandro R et al. Interleukin-36alpha axis is modulated in patients with primary Sjogren‘s syndrome. Clin Exp Immunol 2015; 181(2): 230–238. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12644>.

  23. de Jesus AA, Goldbach-Mansky R. Genetically defined autoinflammatory diseases. Oral Dis 2016; 22(7): 591–604. Dostupné z DOI: <http://dx.doi.org/10.1111/odi.12448>.

  24. Tauber M, Bal E, Pei XY et al. IL36RN Mutations Affect Protein Expression and Function: A Basis for Genotype-Phenotype Correlation in Pustular Diseases. J Invest Dermatol 2016; 136(9): 1811–1819. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jid.2016.04.038>.

  25. Shimizu M, Nakagishi Y, Inoue N et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol 2015; 160(2): 277–281. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clim.2015.06.005>.

  26. Marrakchi S, Guigue P, Renshaw BR et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365(7): 620–628. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1013068>.

  27. Abraham C, Cho JH Inflammatory bowel disease. N Engl J Med 2009; 361(21): 2066–2078. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra0804647>.

  28. Casellas F, Papo M, Guarner F et al. Intracolonic release in vivo of interleukin-1 beta in chronic ulcerative colitis. Clin Sci (Lond) 1995; 89(5): 521–526.

  29. Ludwiczek O, Vannier E, Borggraefe I et al. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol 2004; 138(2): 323–329.

  30. Ludwiczek O, Kaser A, Novick D et al. Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn‘s disease. Eur Cytokine Netw 2005; 16(1): 27–33.

  31. Nunes T, Bernardazzi C, de Souza HS. Interleukin-33 and inflammatory bowel diseases: lessons from human studies. Mediators Inflamm 2014; 2014: 423957. Dostupné z DOI: <http://dx.doi.org/10.1155/2014/423957>.

  32. Hodzic Z, Schill EM, Bolock AM et al. IL-33 and the intestine: The good, the bad, and the inflammatory. Cytokine 2017; 100(10): 1–10. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cyto.2017.06.017>.

  33. Nishida A, Hidaka K, Kanda T et al. Increased Expression of Interleukin-36, a Member of the Interleukin-1 Cytokine Family, in Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22(2): 303–314. Dostupné z DOI: <http://dx.doi.org/10.1097/MIB.0000000000000654>.

  34. Fonseca-Camarillo G, Furuzawa-Carballeda J, Yamamoto-Furusho JK. Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease. Cytokine 2015; 75(2): 389–402. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cyto.2015.04.009>.

  35. Striz I. Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations. Clin Sci (Lond) 2017; 131(17): 2241–2256. Dostupné z DOI: <http://dx.doi.org/10.1042/CS20170098>.

  36. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11(8): 633–652. <http://dx.doi.org/10.1038/nrd3800>.

  37. Van Tassell BW, Abouzaki NA, Oddi Erdle C et al. Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study. J Cardiovasc Pharmacol 2016; 67(6): 544–551. Dostupné z DOI: <http://dx.doi.org/10.1097/FJC.0000000000000378>.

  38. Shakoory B, Carcillo JA, Chatham WW et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome reanalysis of a prior phase iii trials. Crit Care Med 2016; 44(2): 275–281. Dostupné z DOI: <http://dx.doi.org/10.1097/CCM.0000000000001402>.

  39. Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med 2014; 20(Suppl 1): S43-S58. Dostupné z DOI: <http://dx.doi.org/10.2119/molmed.2014.00232>.

  40. Ruperto N, Brunner HI, Quartier P et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367(25): 2396–2406. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1205099>.

  41. Issafras H, Corbin JA, Goldfine ID et al. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1beta antibody with differential receptor-modulating properties. J Pharmacol Exp Ther 2014; 348(1): 202–215. Dostupné z DOI: <http://dx.doi.org/10.1124/jpet.113.205443>.

  42. Ilowite NT, Prather K, Lokhnygina Y et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2014; 66(9): 2570–2579. Dostupné z DOI: <http://dx.doi.org/10.1002/art.38699>.

  43. Kosloski MP, Goss S, Wang SX et al. Pharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT-981 Against IL-1alpha and IL-1beta in Healthy Subjects and Patients With Osteoarthritis of the Knee. J Clin Pharmacol 2016; 56(12): 1582–1590. Dostupné z DOI: <http://dx.doi.org/10.1002/jcph.764>.

  44. Hong DS, Janku F, Naing A et al. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs 2015; 33(3): 621–631. Dostupné z DOI: <http://dx.doi.org/10.1007/s10637–015–0226–6>.

  45. Mistry P, Reid J, Pouliquen I et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin-18 mAb GSK1070806 in healthy and obese subjects. Int J Clin Pharmacol Ther2014; 52(10): 867–879. Dostupné z DOI: <http://dx.doi.org/10.5414/CP202087>.

  46. Argiriadi MA, Xiang T, Wu C et al. Unusual water-mediated antigenic recognition of the proinflammatory cytokine interleukin-18. J Biol Chem 2009; 284(36): 24478–24489. <http://dx.doi.org/10.1074/jbc.M109.023887>.

  47. Tak PP, Bacchi M, Bertolino M. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet 2006; 31(2): 109–116. Dostupné z DOI: <http://dx.doi.org/10.1007/BF03191127>.

Labels
Diabetology Endocrinology Internal medicine
Defensive and damaging inflammation: basic characteristics
Heterogeneity of lymphocytes as central operating units of the immune system
Microbiota, immunity and immunologically-mediated diseases
Primary immunodeficiencies in adults
Secondary immunodeficiency as a consequence of chronic diseases
Treatment of antibody immunodeficiency
Adverse effects of immunoglobulin therapy
Current trends in immunosuppressive treatment
The role of allergology in internal medicine today and vice versa
Anaphylactic symptoms and anaphylactic shock
Article was published in

Internal Medicine

Issue 2
2019 Issue 2
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#